Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

Compare the response rate after 6 months of hormone treatment (or a major change in hormone treatment) in metastatic breast cancer, according to the uptake of FES in metastatic lesions taking-up FDG on PET/CT at baseline. Hypothesis: best response rate will be observed in patients with all metastases taking up FES prior to treatment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Hormones

Criteria

Inclusion Criteria:

• Post menopausal

• age > 17

• WHO 0-2

• Metastatic adenocarcinoma of the breast

• Treated by antihormone treatment during around 5 years withdrawn for at least 3 months OR metastatic cancer at diagnosis having received no more than one line of hormone treatment

• Life expectancy > 6 months

• Hormone-dependent cancer initially demonstrated by hormone receptors in the tumour

• Presence of oestrogen receptors proven with immunohistochemistry (> 10%) and HER2 determined by immunohistochemistry or FISH (on primary tumour or a metastasis)

• Metastatic recurrence on FDG PET dating less than 1 month, confirmed by another modality (contrast-enhanced CT, MRI, ultrasonography, bone scintigraphy or PET/CT, other)

• FDG PET/CT available on PACS or CD DICOM III format 11

• Informed consent obtained

Exclusion Criteria:

• Other evolutive malignant disease or acute or chronic infectious disease

• Chemotherapy during the last 3 months or change in treatment since FDG PET/CT.

• Isolated liver metastasis (high FES uptake by normal liver)